Funding Opportunity PAR-19-169 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.

Funding Opportunity PAR-19-168 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.

Funding Opportunity RFA-CA-19-032 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to advance our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS) through research directed at addressing one of several proposed "Provocative Questions" (PQs). These PQs are not intended to represent the full range of NCI's priorities in HIV/AIDS-related cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems and paradoxes in key areas of AIDS-related cancer research that are deemed important but have not received sufficient attention. Provocative Questions in Cancer with an Underlying HIV Infection involves a set of 6 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

Funding Opportunity RFA-AI-19-006 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a HIV Vaccines Clinical Trials Network Leadership and Operations Center (LOC). The LOC will be responsible for the overall administrative and scientific leadership for the HIV Vaccines Clinical Trials Network.

Funding Opportunity RFA-AI-19-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for HIV/AIDS Clinical Trials Networks Laboratory Centers (LCs). Each LC will be responsible for providing a framework for laboratory leadership, structure and activities that contribute to the development and execution of the laboratory elements of NIAID HIV/AIDS Clinical Trials Networks research agendas.

Funding Opportunity RFA-AI-19-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a HIV Prevention Clinical Trials Network Leadership and Operations Center (LOC). The LOC will be responsible for the overall administrative and scientific leadership for the HIV Prevention Clinical Trials Network.

Funding Opportunity RFA-AI-19-004 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a HIV/AIDS Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network Leadership and Operations Center (LOC). The LOC will be responsible for the overall administrative and scientific leadership for the HIV/AIDS Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network.

Funding Opportunity RFA-AI-19-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a HIV/AIDS Adult Therapeutics Clinical Trials Network Leadership and Operations Center (LOC). The LOC will be responsible for the overall administrative and scientific leadership for the HIV/AIDS Adult Therapeutics Clinical Trials Network.

Funding Opportunity RFA-AI-19-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for HIV/AIDS Clinical Trials Networks Statistical and Data Management Centers (SDMCs). The SDMCs will be responsible for the statistical and data management leadership and coordination critical to the NIAID HIV/AIDS Clinical Trials Networks.

Funding Opportunity PAR-19-170 from the NIH Guide for Grants and Contracts. This purpose of this FOA is to identify risk factors for dementia progression in PDD. Applicants must have access to well-characterized populations of PDD patients that have been followed longitudinally that they can continue to follow with clinical assessments and biospecimen collection until autopsy. Research should propose to identify clinical, pathological and/or biospecimen factors that predict which patients will develop cognitive impairment and/or dementia.

Funding Opportunity RFA-AA-19-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), encourages Research Project Grant (R01) applications proposing to conduct mechanistic studies on the relationships between sleep problems and alcohol dependence. A major impediment for recovery from alcohol use disorder (AUD) is the persistent sleep problems during abstinence promoting relapse. The objective of this FOA is to promote research in animal models and human subjects on the reciprocal relationships between chronic alcohol use and sleep disruptions. The major goal is to understand the underlying mechanisms that will lead to improved treatments for alcohol dependence. NIAAA strongly encourages collaborative efforts between experts in sleep research and established alcohol investigators to facilitate the development of proposals incorporating both areas of research.

Funding Opportunity RFA-DK-19-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development of targeted mass spectrometric assays (e.g., Multiple Reaction Monitoring) for proteins and peptides of primary interest to the obesity research community (e.g., Adiponectin, Leptin, Resistin, Neuropeptide Y, Alpha-melanocyte-stimulating hormone, Peptide YY, Glucagon-like peptide 1, Ghrelin, Adrenocorticotropin, Corticotropin-releasing hormone, Gastrin, Cholecystokinin, Secretin, Vasoactive intestinal peptide, gastric-inhibitory peptide, gastrin-releasing peptide, motilin, pancreatic polypeptide,RBP4,myostatin, FGF21). The proposed assays should be highly reproducible, easily transferable to other laboratories, easy to multiplex, and validated in human plasma or serum.

Funding Opportunity RFA-DK-18-007 from the NIH Guide for Grants and Contracts. This FOA invites applications for planning cooperative agreements (U34) for a national, multisite, observational cohort study to prospectively examine the risk and protective factors for neurocognitive complications of pediatric type 1 diabetes (T1D; onset approximately ages 5-10 years) and a comparison sample. The U34 is designed to: 1) Permit early peer review of the rationale for the proposed cohort study; 2) Permit assessment of the study design; and 3) Provide support for the development of essential elements required for the design and conduct of the cohort study and the management and analysis of the study data. Consultation with NIDDK scientific staff is strongly encouraged prior to the submission of the U34 application.

Notice NOT-AA-19-005 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-047 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-062 from the NIH Guide for Grants and Contracts

Notice NOT-AT-19-020 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-167 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages research to develop, characterize and validate innovative mammalian models that recapitulate molecular, cellular, neuropathological, behavioral and cognitive hallmarks of the Alzheimers Disease-Related Dementias (ADRD), including Lewy body dementia (LBD), vascular contributions to cognitive impairment and dementia (VCID), frontotemporal degeneration (FTD) and mixed etiology dementias (MED). Models will be expected to exhibit a broad range of features characteristic of the dementia disorder being modeled, including a mid- to late-life onset consistent with the human disorder, multiple age-dependent neuropathological processes and the associated behavioral, cognitive and/or physiological abnormalities. For each proposed mammalian model, a relevant suite of phenotypes that inform human ADRD disease progression and mechanisms should be characterized across the full life span or, for longer-living mammalian models, throughout the disease-relevant stages of adulthood. The goal of this FOA is to establish multi-dimensional mammalian models for ADRD to serve as tools to interrogate molecular disease mechanisms and identify therapeutic targets.

Notice NOT-HL-19-675 from the NIH Guide for Grants and Contracts

Notice NOT-AG-19-001 from the NIH Guide for Grants and Contracts